Author

Amir A. Jazaeri

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-4335-4151

Observed ORCID: 0000-0003-4335-4151

OpenAlex ID: A5135837963

Pan-cancer spatial atlas of tertiary lymphoid structures

2026 · Kyung Serk Cho, Yunhe Liu, et al. · Science · 21

Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study

2026 · Helen D. Clark, Michael Frumovitz, et al. · International Journal of Gynecological Cancer · 3

Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer.

2026 · Antonia Busse, Winfried Alsdorf, et al. · Journal of Clinical Oncology · 3

First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma

2026 · Helen D. Clark, Samira Aghlara-Fotovat, et al. · Clinical Cancer Research · 2

Circulating tumor DNA to enhance detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy.

2026 · Helen D. Clark, Sanghoon Lee, et al. · Journal of Clinical Oncology · 1

A phase I, open-label, dose-finding, safety, tolerability, and exploratory trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer.

2026 · Helen D. Clark, Anne Knisely, et al. · Journal of Clinical Oncology

Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment.

2026 · Jeffrey Andrew How, Morgan Bou Zerdan, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 30

H-index: 3

I10-index: 1